Introduction To evaluate the effects of a new lubricating, antioxidant solution (VisuEvo(R)) on dry eye disease (DED) in patients undergoing cataract surgery. Methods Patients requiring cataract surgery with either healthy ocular surface or mild DED (tear break-up time, TBUT > 7, Schirmer I test > 15 mm/5 min) were enrolled in this multicenter, open-label, randomized, prospective study. Scheduled visits were 2 weeks before surgery (screening), day of surgery (V0), week 1 (V1), and 2 (V2) after surgery. VisuEvo(R) was self-administered three times daily for the whole study duration (group A); the control group (group B) had no tear substitute administration. The primary endpoint was the change in TBUT over time; the secondary endpoints were changes in Ocular Surface Disease Index (OSDI), ocular surface staining, the Schirmer I test, and osmometry. Results A total of 45 patients were included (group A, 23; group B, 22; age 74 +/- 8 years). At the screening, TBUT was similar between the groups (group A, 8.5 +/- 1.8 s; group B, 7.8 +/- 0.7, p = 0.11). At the scheduled visits, TBUT increase vs screening visit was significantly higher in group A: +1.2 s at V0, +1.4 s at V1, and +1.9 s at V2 (p < 0.01). Also, OSDI was significantly lower in group A at V0, V1, and V2 (p < 0.027). After surgery, corneal staining was absent in 65-78% of group A compared with 54-59% in group B. The two groups did not show any significant differences of osmometry and the Schirmer I test. Conclusions The ocular surface was more protected and quickly restored from surgery when VisuEvo(R) was used from 2 weeks preoperatively to 2 weeks postoperatively.

New Therapeutic Strategy and Innovative Lubricating Ophthalmic Solution in Minimizing Dry Eye Disease Associated with Cataract Surgery: A Randomized, Prospective Study / P. Fogagnolo, E. Favuzza, D. Marchina, M. Cennamo, R. Vignapiano, C. Quisisana, L. Rossetti, R. Mencucci. - In: ADVANCES IN THERAPY. - ISSN 0741-238X. - 37:4(2020 Apr 01), pp. 1664-1674. [10.1007/s12325-020-01288-z]

New Therapeutic Strategy and Innovative Lubricating Ophthalmic Solution in Minimizing Dry Eye Disease Associated with Cataract Surgery: A Randomized, Prospective Study

Fogagnolo, Paolo;Marchina, Daniele;Rossetti, Luca;
2020-04-01

Abstract

Introduction To evaluate the effects of a new lubricating, antioxidant solution (VisuEvo(R)) on dry eye disease (DED) in patients undergoing cataract surgery. Methods Patients requiring cataract surgery with either healthy ocular surface or mild DED (tear break-up time, TBUT > 7, Schirmer I test > 15 mm/5 min) were enrolled in this multicenter, open-label, randomized, prospective study. Scheduled visits were 2 weeks before surgery (screening), day of surgery (V0), week 1 (V1), and 2 (V2) after surgery. VisuEvo(R) was self-administered three times daily for the whole study duration (group A); the control group (group B) had no tear substitute administration. The primary endpoint was the change in TBUT over time; the secondary endpoints were changes in Ocular Surface Disease Index (OSDI), ocular surface staining, the Schirmer I test, and osmometry. Results A total of 45 patients were included (group A, 23; group B, 22; age 74 +/- 8 years). At the screening, TBUT was similar between the groups (group A, 8.5 +/- 1.8 s; group B, 7.8 +/- 0.7, p = 0.11). At the scheduled visits, TBUT increase vs screening visit was significantly higher in group A: +1.2 s at V0, +1.4 s at V1, and +1.9 s at V2 (p < 0.01). Also, OSDI was significantly lower in group A at V0, V1, and V2 (p < 0.027). After surgery, corneal staining was absent in 65-78% of group A compared with 54-59% in group B. The two groups did not show any significant differences of osmometry and the Schirmer I test. Conclusions The ocular surface was more protected and quickly restored from surgery when VisuEvo(R) was used from 2 weeks preoperatively to 2 weeks postoperatively.
Cataract surgery; Dry eye disease; Lubricating eye drops; Ocular surface; Ophthalmology
Settore MED/30 - Malattie Apparato Visivo
17-mar-2020
ADVANCES IN THERAPY
Article (author)
File in questo prodotto:
File Dimensione Formato  
Fogagnolo2020_Article_NewTherapeuticStrategyAndInnov.pdf

accesso aperto

640.81 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/723755
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact